Top

Published in:

01-07-2009 | Short Communication

Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma

Authors: Y. Diaz, A. Gonzalez, A. Lopez, R. Perez, A. M. Vazquez, E. Montero

Published in: Cancer Immunology, Immunotherapy | Issue 7/2009

Abstract

Anti-idiotype monoclonal antibody (mAb) 1E10 was generated by immunizing BALB/c mice with an Ab1 mAb which recognizes NeuGc-containing gangliosides, sulfatides and some tumor antigens. 1E10 mAb induces therapeutic effects in a primary breast carcinoma and a melanoma model. However, the tumor immunity mechanisms have not been elucidated. Here we show that aluminum hydroxide-precipitated 1E10 mAb immunization induced anti-metastatic effect in the 3LL-D122 Lewis Lung carcinoma, a poorly immunogenic and highly metastatic model in C57BL/6 mice. The therapeutic effect was associated to the increment of T cells infiltrating metastases, the reduction of new blood vessels formation and the increase of apoptotic tumor cells in lung nodules. Interestingly, active immunization does not induce measurable antibodies to the 1E10 mAb, the NeuGc-GM3 or tumor cells, which may suggest a different mechanism which has to be elucidated. These findings may support the relevance of this target for cancer biotherapy.

Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C(1–2):373–389

Dunn PL, Johnson CA, Styles JM, Pease SS, Dean CJ (1987) Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge. Immunology 60(2):181–186PubMed

Jinnohara T, Tsujisaki M, Sasaki S, Hinoda Y, Taniguchi M, Imai K (1998) Anti-tumor effect of internal image bearing anti-idiotypic monoclonal antibody in relation to GM3 ganglioside. Int J Cancer 76(3):345–353PubMedCrossRef

Denton GW, Durrant LG, Hardcastle JD, Austin EB, Sewell HF, Robins RA (1994) Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 57(1):10–14PubMedCrossRef

Durrant LG, Doran M, Austin EB, Robins RA (1995) Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours. Int J Cancer 61(1):62–66PubMedCrossRef

Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H (1995) Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 92(11):4773–4777PubMedCrossRef

Durrant LG, Buckley DJ, Robins RA, Spendlove I (2000) 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. Int J Cancer 85(1):87–92PubMedCrossRef

Reinartz S, Kohler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Mobus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U (2004) Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10(5):1580–1587PubMedCrossRef

Vazquez AM, Alfonso M, Lanne B, Karlsson KA, Carr A, Barroso O, Fernandez LE, Rengifo E, Lanio ME, Alvarez C et al (1995) Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 14(6):551–556PubMed

10.

Vazquez AM, Gabri MR, Hernandez AM, Alonso DF, Beausoleil I, Gomez DE, Perez R (2000) Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep 7(4):751–756PubMed

11.

Alfonso M, Diaz A, Hernandez AM, Perez A, Rodriguez E, Bitton R, Perez R, Vazquez AM (2002) An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 168(5):2523–2529PubMed

12.

Neninger E, Diaz RM, de la Torre A, Rives R, Diaz A, Saurez G, Gabri MR, Alonso DF, Wilkinson B, Alfonso AM, Combet T, Perez R, Vazquez AM (2007) Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 6(2):145–150PubMed

13.

Vazquez AM, Perez A, Hernandez AM, Macias A, Alfonso M, Bombino G, Perez R (1998) Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 17(6):527–534PubMed

14.

Hernandez AM, Rodriguez M, Lopez-Requena A, Beausoleil I, Perez R, Vazquez AM (2005) Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: a self versus non-self-matter. Immunobiology 210(1):11–21PubMedCrossRef

15.

Diaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, Diaz RM, Perez R, Vazquez AM (2003) Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107(2):80–89PubMedCrossRef

16.

Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, Muchmore EA, Nelson DL, Warren ST, Varki A (1998) A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 95(20):11751–11756PubMedCrossRef

17.

Ledeen RW, Yu RK (1982) Gangliosides: structure, isolation, and analysis. Methods Enzymol 83:139–191PubMedCrossRef

18.

Olson MV, Varki A (2003) Sequencing the chimpanzee genome: insights into human evolution and disease. Nat Rev Genet 4(1):20–28PubMedCrossRef

19.

Stults CL, Sweeley CC, Macher BA (1989) Glycosphingolipids: structure, biological source, and properties. Methods Enzymol 179:167–214PubMedCrossRef

20.

Eisenbach L, Hollander N, Greenfeld L, Yakor H, Segal S, Feldman M (1984) The differential expression of H-2 K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 34(4):567–573PubMedCrossRef

21.

Alfonso M, Vazquez AM, Carr A, Haerslev T, Fernandez LE, Lanio ME, Alvarez C, Zeuthen J, Perez R (1995) T cell-independent B cell response to self-monosialogangliosides: primary response monoclonal antibodies. Hybridoma 14(3):209–216PubMedCrossRef

22.

Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21(3):505–515PubMedCrossRef

23.

Kohlgraf KG, Gawron AJ, Higashi M, VanLith ML, Shen X, Caffrey TC, Anderson JM, Hollingsworth MA (2004) Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol Immunother 53(12):1068–1084PubMedCrossRef

24.

Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, Niu T, Liu F, Jiang Y, Hu B, Wu Y, Su JM, Lou YY, He QM, Wen YJ, Yang JL, Kan B, Mao YQ, Luo F, Peng F (2003) Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102(5):1815–1823PubMedCrossRef

25.

Birebent B, Mitchell E, Akis N, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai D, Zhang T, Herlyn DM (2003) Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17–1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine 21(15):1601–1612PubMedCrossRef

26.

Pride MW, Shuey S, Grillo-Lopez A, Braslawsky G, Ross M, Legha SS, Eton O, Buzaid A, Ioannides C, Murray JL (1998) Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res 4(10):2363–2370PubMed

27.

Wagner U, Kohler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack HJ, Mobus V, Kreienberg R, Bauknecht T, Krebs D, Wallwiener D (2001) Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 7(5):1154–1162PubMed

28.

Livingston PO, Ragupathi G (1997) Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 45(1):10–19PubMedCrossRef

29.

Chapman PB (2003) Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Investig Drugs 4(6):710–715PubMed

30.

Ishioka GY, Lamont AG, Thomson D, Bulbow N, Gaeta FC, Sette A, Grey HM (1992) MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol 148(8):2446–2451PubMed

31.

Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G (1999) Self glycolipids as T-cell autoantigens. Eur J Immunol 29(5):1667–1675PubMedCrossRef

32.

Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB (2003) Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 198(1):173–181PubMedCrossRef

33.

Mazorra Z, Mesa C, Fernandez A, Fernandez LE (2008) Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge. Cancer Immunol Immunother 57(12):1771–1780PubMedCrossRef

34.

Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vazquez AM, Fainboim L (2006) Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 29(2):215–223PubMedCrossRef

35.

Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2(7):521–528PubMedCrossRef

36.

Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102(2):430–437PubMedCrossRef

37.

Perez A, Mier ES, Vispo NS, Vazquez AM, Perez Rodriguez R (2002) A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells. Mol Immunol 39(1–2):103–112PubMedCrossRef

38.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMedCrossRef

39.

Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909–918PubMedCrossRef

40.

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027PubMedCrossRef

41.

Klasa RJ, Gillum AM, Klem RE, Frankel SR (2002) Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12(3):193–213PubMedCrossRef

42.

Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23(5):1028–1043PubMedCrossRef

43.

Amin S, Robins RA, Maxwell-Armstrong CA, Scholefield JH, Durrant LG (2000) Vaccine-induced apoptosis: a novel clinical trial end point? Cancer Res 60(12):3132–3136PubMed

44.

Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170(10):4905–4913PubMed

45.

Roque-Navarro L, Chakrabandhu K, de Leon J, Rodriguez S, Toledo C, Carr A, de Acosta CM, Hueber AO, Perez R (2008) Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 7(7):2033–2041PubMedCrossRef

46.

Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A (2002) Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 101(6):567–575PubMedCrossRef

47.

Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, Hicklin DJ, Ellis LM (2002) Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38(8):1133–1140PubMedCrossRef

48.

Komita H, Homma S, Saotome H, Zeniya M, Ohno T, Toda G (2006) Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8⁺ T cells directly induces apoptosis of mouse hepatocellular carcinoma. J Hepatol 45(5):662–672PubMedCrossRef

49.

Dorothee G, Vergnon I, Menez J, Echchakir H, Grunenwald D, Kubin M, Chouaib S, Mami-Chouaib F (2002) Tumor-infiltrating CD4⁺ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J Immunol 169(2):809–817PubMed

50.

Manjili MH (2007) Come forth 1E10 anti-idiotype vaccine: delivering the promise to immunotherapy of small cell lung cancer. Cancer Biol Ther 6(2):151–152PubMed

51.

Alfonso S, Diaz RM, de la Torre A, Santiesteban E, Aguirre F, Perez K, Rodriguez JL, Barroso MD, Hernandez AM, Toledo D, Gabri MR, Alonso DF, Viada C, Gomez RE, Suarez E, Vazquez AM, Perez R, Macias AE (2007) 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 6(12):1847–1852PubMedCrossRef

52.

Gasparini G, Longo R, Fanelli M, Teicher BA (2005) Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23(6):1295–1311PubMedCrossRef

53.

Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16(8):2659–2671PubMed

54.

Teicher BA (1999) Potentiation of cytotoxic cancer therapies by antiangiogenic agents. Humana Press Inc, Totowa

55.

Woude GF, Kelloff GJ, Ruddon RW, Koo HM, Sigman CC, Barrett JC, Day RW, Dicker AP, Kerbel RS, Parkinson DR, Slichenmyer WJ (2004) Reanalysis of cancer drugs: old drugs, new tricks. Clin Cancer Res 10(11):3897–3907PubMedCrossRef

Title: Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma
Authors: Y. Diaz
A. Gonzalez
A. Lopez
R. Perez
A. M. Vazquez
E. Montero
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 7/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-008-0634-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2009

A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells

Peroxisome proliferator-activated receptor gamma overexpression and knockdown: impact on human B cell lymphoma proliferation and survival

Reduced levels of recent thymic emigrants in acute myeloid leukemia patients

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma

FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck

Intratumoral interferon-α gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer